 phase clinic trial pediatr patient acut leukemia toxic clinic efficaci children relaps refractori leukemia phase trial continu infus dose studi children acut leukemia dose-limit toxic myelosuppress dose level patient fatal system bacteri fungal infect dose level signific oncolyt respons patient addit signific correl respons cell type dose oncolyt respons acut myeloid leukemia aml patient acut lymphoblast leukemia all patient phase trial patient refractori diseas aml patient complet hematolog respons patient partial respons addit dose-respons relationship patient improv cytoreduct peripher blast cell dose vitro evalu uptak anabol leukem blast cell patient cld-amp cldatp concentr steady-st level hour intracellular nucleotid disappear rate high half-liv hour cldamp cldatp continu infus necessari desir plasma concentr result studi antileukem activ lack prohibit nonhematolog toxic phase II trial patient aml all